BioCentury
ARTICLE | Company News

Fate, MSKCC researching engineered pluripotent cells

September 7, 2016 7:00 AM UTC

Fate Therapeutics Inc. (NASDAQ:FATE) partnered with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T cell immunotherapies derived from engineered pluripotent cell lines. Under the three-year deal, Fate said the groups will seek to create pluripotent cell lines that are engineered for "enhanced antigen specificity and functionality" and work to optimize T cell differentiation protocols.

Fate said the partnership will combine its experience in pluripotent cell generation, engineering and differentiation with MSKCC's cell-based immunotherapy manufacturing and delivery expertise. Michel Sadelain, director of MSKCC's Center for Cell Engineering, will lead the research. ...